Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Peptides Stories

2011-02-09 01:09:17

Researchers at the University at Buffalo have devised two new ways of "stapling" peptide helices to prevent these medically important molecules from losing their shape and degrading in the presence of enzymes. The discovery could help speed the development of peptide-based drugs against diseases including cancer. UB scientists say the methods they pioneered are simpler than existing techniques, one of which employs an expensive ruthenium catalyst to connect chemical side chains that protrude...

2011-01-03 09:00:00

WALTHAM, Massachusetts and LELYSTAD, The Netherlands, January 3, 2011 /PRNewswire/ -- Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator's 'Homing Peptides'...

2010-12-01 06:28:00

DUBLIN, Dec. 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE). The study showed that patients receiving treatment with Firazyr experienced a significantly faster time to onset of symptom relief from...

2010-12-01 06:00:00

DUBLIN, December 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of FIRAZYR(R) (icatibant) for treatment of acute attacks of hereditary angioedema (HAE). The study showed that patients receiving treatment with FIRAZYR experienced a significantly faster time to onset of symptom...

2010-11-23 09:17:00

BASKING RIDGE, N.J., Nov. 23, 2010 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the 22nd Annual Piper Jaffray Health Care Conference. Dr. Mazzo's presentation will be given at the New York Palace Hotel in the Kennedy 2 Room in New York City on Tuesday, November 30, 2010 at 9:30 a.m. EST. Additionally, Dr. Mazzo will be...

2010-11-17 09:30:00

BASKING RIDGE, N.J., Nov. 17, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting on November 17, 2010 at 9:30 a.m. CST in Chicago, IL. The...

2010-11-16 10:45:00

BASKING RIDGE, N.J., Nov. 16, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, Ph.D., Duke University Medical Center, presented an abstract at the AHA Scientific Sessions meeting on November 16, 2010 at 10:45 a.m. CST in Chicago, IL. The abstract, entitled "RB006, a Direct Factor IX Inhibitor Results in Consistent and Near Complete Inhibition of Factor...

2010-11-15 21:43:53

Biologists at UC San Diego and four other institutions have identified a long-sought after family of genes that controls how yeast and plants accumulate toxic heavy metals and arsenic inside their cells. Their discovery, published in two separate scientific papers, is a significant advance with the potential to restore environmentally damaged waste sites and protect the food supply from toxic metal contamination. It could permit scientists to engineer plants capable of removing toxic metals...

2010-11-15 11:00:00

BASKING RIDGE, N.J., Nov. 15, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced today two abstract presentations evaluating the potency and duration of a subcutaneous depot formulation of pegnivacogin (a.k.a. RB006), a nuclease-stabilized aptamer and direct Factor IXa inhibitor. The studies were presented at the American Heart Association (AHA) Scientific Sessions meeting, on...

2010-11-10 13:44:00

PALO ALTO, Calif., Nov. 10, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today it will report data from the Phase 2 randomized multicenter study of Telintra® (ezatiostat HCl) tablets in the treatment of patients with Myelodysplastic Syndrome at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL. Details of the presentation are as follows: Abstract #2910 -Myelodysplastic Syndromes: Poster II; Sunday, December 5,...